4-(4-Butoxy-phenyl)-pyridine | 4357-33-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-(4-Butoxy-phenyl)-pyridine
• 英文别名: 4-(4-butoxyphenyl)pyridine
• CAS: 4357-33-9
• 化学式: C₁₅H₁₇NO
• 分子量: 227.306
• InChiKey: CFJNAALMLFXEDF-UHFFFAOYSA-N

物化性质

• 熔点：
  58.5-59.5 °C
• 沸点：
  351.6±25.0 °C(Predicted)
• 密度：
  1.026±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(4-Butoxy-phenyl)-pyridine 在 一溴化碘 作用下， 以 正己烷 、 氯仿 为溶剂， 生成
  参考文献：
  名称：

  由 4-烷氧基苯基吡啶与碘和卤间化合物形成的卤键液晶复合物

  摘要：

  在 4-烷氧基苯基-4-吡啶和碘以及卤间化合物 ICl 和 IBr 之间形成强卤素键合的络合物，每个例子的特征都是单晶 X 射线晶体学。在加热时，除了一个复合物外，所有复合物都显示出液晶近晶 A 相，尽管有证据表明材料通过中间相加热时会发生分解。对于这样的短分子，中间相相当稳定，小角度 X 射线散射表明复合物在中间相中形成一种反平行的、头对头的二聚体排列。

  DOI：

  10.1039/d2ce01555b
• 作为产物：
  描述：

  1-碘丁烷 、 4-吡啶基苯酚 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以86%的产率得到4-(4-Butoxy-phenyl)-pyridine
  参考文献：
  名称：

  Pyrazole and Isoxazole Derivatives as New, Potent, and Selective 20-Hydroxy-5,8,11,14-eicosatetraenoic Acid Synthase Inhibitors

  摘要：

  In a previous paper, we reported the N-hydroxyformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor. Despite its attraction as a potential therapeutic agent for cerebral diseases, the preparation of an injectable formulation of HET0016 was limited by its poor solubility under neutral conditions and instability under acidic conditions. The instability of HET0016 in acidic conditions is due to the N-hydroxyformamidine moiety, which is considered to be essential for the potent and selective activity seen in our previous study. The activity was maintained when the N-hydroxyformamidine moiety was replaced by an imidazole ring (3a; IC50 = 5.7 +/- 1.0 nM), but this was associated with a loss of selectivity for cytochrome P450s (CYPs). However, other azole derivatives such as isoxazole derivative 23 (IC50 value 38 +/- 10 nM) and pyrazole derivative 24 (IC50 value 23 +/- 12 nM) showed potent and selective activities with improved stability.

  DOI：

  10.1021/jm020557k

文献信息

• METHODS OF MODULATING CELL PROLIFERATION AND CYST FORMATION IN POLYCYSTIC KIDNEY AND LIVER DISEASES
  申请人：The Medical College of Wisconsin, Inc.

  公开号：EP2061450B1

  公开（公告）日：2017-04-19
• Methods of modulating cell proliferation and cyst formation in polycystic kidney and liver diseases
  申请人：Sweeney William E.

  公开号：US20080167382A1

  公开（公告）日：2008-07-10

  The present invention provides a method for preferentially reducing the proliferation of cystic epithelial cells in the kidney or bile duct in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to preferentially reduce the proliferation of cystic epithelial cells over normal epithelial cells such as tubule epithelial cells in the kidney or bile duct. The present invention also provides a method for preventing or treating autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), ARPKD associated congenital hepatic fibrosis, ARPKD associated Caroli's disease, or cholangiocarcinoma in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to prevent or treat the disease.
• Methods of Modulating Cell Proliferation and Cyst Formation in Polycystic Kidney and Liver Diseases
  申请人：Sweeney William E.

  公开号：US20140329811A1

  公开（公告）日：2014-11-06

  The present invention provides a method for preferentially reducing the proliferation of cystic epithelial cells in the kidney or bile duct in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to preferentially reduce the proliferation of cystic epithelial cells over normal epithelial cells such as tubule epithelial cells in the kidney or bile duct. The present invention also provides a method for preventing or treating autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), ARPKD associated congenital hepatic fibrosis, ARPKD associated Caroli's disease, or cholangiocarcinoma in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to prevent or treat the disease.
• US8846764B2
  申请人：——

  公开号：US8846764B2

  公开（公告）日：2014-09-30
• US9511072B2
  申请人：——

  公开号：US9511072B2

  公开（公告）日：2016-12-06